FDA Adverse Event Injury Summary report: N

COREVALVE

MDR report key: 3831090 · Received May 23, 2014

Report

Report Number
2025587-2014-00322
Event Type
Injury
Date Received
May 23, 2014
Date of Event
April 27, 2014
Report Date
April 30, 2014
Manufacturer
MEDTRONIC HEART VALVES DIVISION
Product Code
NPT
PMA / PMN Number
P130021
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
NY, US
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

IF INFORMATION IS PROVIDED IN THE FUTURE, A SUPPLEMENTAL REPORT WILL BE ISSUED.

Additional Manufacturer Narrative · 1

PRODUCT ANALYSIS: THE PRODUCT REMAINS IMPLANTED, THEREFORE NO PRODUCT ANALYSIS CAN BE PERFORMED. CONCLUSION: PER THE INSTRUCTIONS FOR USE (IFU), CONDUCTION DISTURBANCES ARE A POTENTIAL PROCEDURAL COMPLICATION AND ARE ASSOCIATED WITH ANY CARDIAC OR THORACIC PROCEDURE, OPEN OR CATHETER-BASED, AND CAN BE RESOLVED WITH MEDICAL TREATMENT OR THE IMPLANT OF A PERMANENT PACEMAKER. ACCORDING TO LITERATURE REVIEW AND THE VALVE ACADEMIC RESEARCH CONSORTIUM (VARC), THE CLOSE ANATOMICAL RELATIONSHIP BETWEEN THE AORTIC VALVE COMPLEX AND THE BRANCHING ATRIOVENTRICULAR BUNDLE MAY PROVIDE AN EXPLANATION FOR THESE COMPLICATIONS OF THE PROCEDURE. OTHER FACTORS THAT COULD CONTRIBUTE TO THE ONSET OF CONDUCTION DEFECTS INCLUDE UNDERLYING HEART DISEASE, ELECTROLYTE DISTURBANCES AND CERTAIN MEDICATIONS (I.E. BETA BLOCKERS, CALCIUM CHANNEL BLOCKERS). IN THIS CASE, THE EXACT CAUSE OF THE REPORTED CLINICAL OBSERVATION CANNOT BE CONFIRMED. (B)(4).

Description of Event or Problem · 1

MEDTRONIC RECEIVED INFORMATION THAT THREE DAYS FOLLOWING THE IMPLANT OF THIS TRANSCATHETER BIOPROSTHETIC VALVE THE PATIENT DEVELOPED SLOW ATRIAL FIBRILLATION. SUBSEQUENTLY, A PERMANENT PACEMAKER WAS IMPLANTED TWO DAYS LATER. NO OTHER ADVERSE PATIENT EFFECTS WERE REPORTED.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
308074 COREVALVE AORTIC VALVE, PROSTHESIS, PERCUTANEOUSLY DELIVERED NPT MEDTRONIC HEART VALVES DIVISION MCS-P3-943

Patients

Seq Age Sex Outcome Treatment
1 00086 YR Required Intervention